Valsartan Tablets can be taken with or without food.
In these patients, the addition of valsartan to established therapies for atrial fibrillation and for coexisting cardiovascular conditions did not reduce the risk of either a first recurrence or multiple recurrences of atrial fibrillation.
Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.
Controlled studies in pregnant women show no evidence of fetal risk. Store it at room temperature and away from excess heat and moisture not in the bathroom.
Valsartan is in a class of medications called angiotensin II receptor antagonists. Valsartan selectively acts on AT1 , the subtype receptor that mediates the cardiovascular actions of angiotensin II, the main vasoactive hormone of the renin-angiotensin-system. Absolute bioavailability for valsartan is approximately 25 ranges between 10 -35. The most common side effects associated with valsartan are dizziness, hypotension, high levels of potassium in the blood hyperkalemia and increased blood creatinine.
Ask your doctor before use if you are taking the following medications:
Tell your doctor if you drink alcohol.
Taking this medicine can increase your risk of blood clots, stroke, or heart attack.
In some cases, symptoms may worsen temporarily following discontinuation of therapy.
The patient should be monitored for hypertensive reactions for two weeks or until 24 hours after the last dose of methylene blue, whichever comes first.
Valsartan does not accumulate appreciably in plasma following repeated administration. AF trial, we tested the effect of an ARB, valsartan, on the recurrence of atrial fibrillation in patients who had a history of atrial fibrillation associated with cardiovascular disease, diabetes, or left atrial enlargement. Angiotensin System for Prevention of Atrial Fibrillation.
Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while decreasing potassium excretion. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.